Genetic heterogeneity in Cornelia de Lange syndrome (CdLS) and CdLS-like phenotypes with observed and predicted levels of mosaicism.
Ansari M., Poke G., Ferry Q., Williamson K., Aldridge R., Meynert AM., Bengani H., Chan CY., Kayserili H., Avci S., Hennekam RCM., Lampe AK., Redeker E., Homfray T., Ross A., Falkenberg Smeland M., Mansour S., Parker MJ., Cook JA., Splitt M., Fisher RB., Fryer A., Magee AC., Wilkie A., Barnicoat A., Brady AF., Cooper NS., Mercer C., Deshpande C., Bennett CP., Pilz DT., Ruddy D., Cilliers D., Johnson DS., Josifova D., Rosser E., Thompson EM., Wakeling E., Kinning E., Stewart F., Flinter F., Girisha KM., Cox H., Firth HV., Kingston H., Wee JS., Hurst JA., Clayton-Smith J., Tolmie J., Vogt J., Tatton-Brown K., Chandler K., Prescott K., Wilson L., Behnam M., McEntagart M., Davidson R., Lynch S-A., Sisodiya S., Mehta SG., McKee SA., Mohammed S., Holden S., Park S-M., Holder SE., Harrison V., McConnell V., Lam WK., Green AJ., Donnai D., Bitner-Glindzicz M., Donnelly DE., Nellåker C., Taylor MS., FitzPatrick DR.
BACKGROUND: Cornelia de Lange syndrome (CdLS) is a multisystem disorder with distinctive facial appearance, intellectual disability and growth failure as prominent features. Most individuals with typical CdLS have de novo heterozygous loss-of-function mutations in NIPBL with mosaic individuals representing a significant proportion. Mutations in other cohesin components, SMC1A, SMC3, HDAC8 and RAD21 cause less typical CdLS. METHODS: We screened 163 affected individuals for coding region mutations in the known genes, 90 for genomic rearrangements, 19 for deep intronic variants in NIPBL and 5 had whole-exome sequencing. RESULTS: Pathogenic mutations [including mosaic changes] were identified in: NIPBL 46  (28.2%); SMC1A 5  (3.1%); SMC3 5  (3.1%); HDAC8 6  (3.6%) and RAD21 1  (0.6%). One individual had a de novo 1.3 Mb deletion of 1p36.3. Another had a 520 kb duplication of 12q13.13 encompassing ESPL1, encoding separase, an enzyme that cleaves the cohesin ring. Three de novo mutations were identified in ANKRD11 demonstrating a phenotypic overlap with KBG syndrome. To estimate the number of undetected mosaic cases we used recursive partitioning to identify discriminating features in the NIPBL-positive subgroup. Filtering of the mutation-negative group on these features classified at least 18% as 'NIPBL-like'. A computer composition of the average face of this NIPBL-like subgroup was also more typical in appearance than that of all others in the mutation-negative group supporting the existence of undetected mosaic cases. CONCLUSIONS: Future diagnostic testing in 'mutation-negative' CdLS thus merits deeper sequencing of multiple DNA samples derived from different tissues.